Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 10:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 134 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Paroxetine; Paxil Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Stepped Care for Depression and Musculoskeletal Pain

NCT00118430
View directory record Official record
Conditions
Pain, Depression
Interventions
Stepped Care, Antidepressants, Usual Care
Behavioral · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)

NCT01715805
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Cariprazine, Placebo, Antidepressant Therapy (ADT)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
83
States / cities
Tucson, Arizona • Little Rock, Arkansas • Cerritos, California + 68 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

Treatment of Depression in Parkinson's Disease Trial

NCT00062738
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
paroxetine, Nortriptyline, placebo
Drug · Other
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
35 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 24, 2015 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study of Paxil Use in Menopausal Women

NCT00225914
View directory record Official record
Conditions
Menopause
Interventions
Paroxetine, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years and older · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2010 · Synced Oct 6, 2026, 10:38 AM EDT
Terminated Not applicable Interventional Results available

Prazosin vs Paroxetine in Combat Stress-Related Post-Traumatic Stress Disorder (PTSD) Nightmares & Sleep Disturbance

NCT00202449
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Sleep Disorders
Interventions
prazosin, paroxetine, Placebo
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 50 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Fort Lewis, Washington
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 6, 2026, 10:38 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study

NCT01944657
View directory record Official record
Conditions
1. Major Depressive Disorder
Interventions
Supplemental TMS, Standard Medication Monotherapy
Device · Drug
Lead sponsor
Sheppard Pratt Health System
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Towson, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 6, 2026, 10:38 AM EDT
Withdrawn Phase 2 Interventional

Pharmacogenetic Clinical Trial of Nepicastat for Post Traumatic Stress Disorder (PTSD)

NCT00641511
View directory record Official record
Conditions
Post Traumatic Stress Disorder (PTSD)
Interventions
SYN117 (nepicastat), Placebo comparator
Drug
Lead sponsor
Michael E. DeBakey VA Medical Center
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Tuscaloosa, Alabama • Charleston, South Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 4 Interventional

Major Depressive Disorder Study In Adults

NCT00049972
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
paroxetine CR
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
71
States / cities
Birmingham, Alabama • Fairfield, Alabama • Mobile, Alabama + 63 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2017 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Results available

Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study

NCT01748955
View directory record Official record
Conditions
Depression, Suicidal Ideation
Interventions
Paroxetine CR for Major Depressive Episode, Bupropion XL for Major Depressive Episode
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 6, 2026, 10:38 AM EDT
Terminated Phase 3 Interventional

Fixed Dose Study of PD 0332334 and Paroxetine for the Treatment of Generalized Anxiety Disorder

NCT00836069
View directory record Official record
Conditions
Anxiety Disorders
Interventions
No drug name provided by Sponsor; drug referenced as PD 0332334, Paroxetine, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Oct 6, 2026, 10:38 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

A Comparison of Prolonged Exposure Therapy, Pharmacotherapy, and Their Combination for PTSD

NCT04961190
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Prolonged Exposure Therapy, Pharmacotherapy with paroxetine or venlafaxine XR
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
304 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
7
States / cities
Birmingham, Alabama • Menlo Park, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate the Efficacy, Safety & Tolerability of Brexpiprazole in the Maintenance Treatment of Adults With Major Depressive Disorder

NCT03538691
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Brexpiprazole, Antidepressant therapy
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

NCT02932904
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Vortioxetine, Paroxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 40 Years
Enrollment
361 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
15
States / cities
Encino, California • Long Beach, California • Torrance, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2018 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 4 Interventional

Paroxetine and Interpersonal Psychotherapy for Maintaining Health and Well-being in Elderly Individuals With Depression

NCT00178100
View directory record Official record
Conditions
Unipolar Depression
Interventions
Interpersonal Psychotherapy, paroxetine
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
69 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 6, 2026, 10:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

NCT07070232
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BNT326, Pumitamig, Itraconazole, Paroxetine
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
1,438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
19
States / cities
Phoenix, Arizona • San Francisco, California • Hartford, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 6, 2026, 10:38 AM EDT
Terminated Phase 4 Interventional

Neural Correlates of Early Intervention for Posttraumatic Stress Disorder (PTSD)

NCT00665678
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
paroxetine, placebo
Drug
Lead sponsor
Foundation for Atlanta Veterans Education and Research, Inc.
Other
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 11, 2012 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Biological Aspects of Depression and Antidepressant Drugs

NCT00018733
View directory record Official record
Conditions
Depression
Interventions
paroxetine, Desipramine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
21 Years to 69 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2001
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 2 Interventional Results available

eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients

NCT02458690
View directory record Official record
Conditions
Depression, Major Depressive Disorder, Dysthymic Disorder, Depressive Symptoms, Cardiovascular Diseases, Heart Diseases, Coronary Artery Disease, Stroke
Interventions
Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications, Usual Care
Behavioral · Drug · Other
Lead sponsor
Indiana University
Other
Eligibility
50 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 19, 2023 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 3 Interventional

Seroquel in Bipolar Depression Versus SSRI

NCT00119652
View directory record Official record
Conditions
Bipolar Disorder, Bipolar Depression, Depression
Interventions
quetiapine fumarate (Seroquel), paroxetine, mood stabilizing activity
Drug · Behavioral
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
676 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
28
States / cities
Phoenix, Arizona • Little Rock, Arkansas • National City, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of MNTX on CYP450 2D6 in Metabolizers of Dextromethorphan

NCT01367535
View directory record Official record
Conditions
Healthy Adults
Interventions
SC Methylnaltrexone (MNTX), IV Methylnaltrexone (MNTX), Oral Paroxetine, SC Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Tarrytown, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 2Phase 3 Interventional

Comparing Paroxetine and Duloxetine on Cardiovascular Measures

NCT00136383
View directory record Official record
Conditions
Depressive Symptoms
Interventions
paroxetine versus duloxetine
Drug
Lead sponsor
Duke University
Other
Eligibility
20 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 6, 2026, 10:38 AM EDT
Active, not recruiting Phase 4 Interventional

Management of Acute Tinnitus With Migraine Medications

NCT06799169
View directory record Official record
Conditions
Tinnitus
Interventions
Nortriptyline, Topiramate, Paroxetine, Verapamil
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
25 Years to 85 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Paroxetine Hydrochloride Controlled-Release Tablets 25 mg to Paxil CR™ Tablets 25 mg

NCT00647881
View directory record Official record
Conditions
Healthy
Interventions
Paroxetine Hydrochloride Controlled-Release Tablets 25 mg, Paxil CR™ Tablets 25 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 6, 2026, 10:38 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Role of Dopamine Metabolism in the Antidepressant Effects of Sleep Deprivation and Sertraline in Depressed Patients

NCT00581009
View directory record Official record
Conditions
Major Depressive Disorder, Bipolar Disorder
Interventions
chronobiological augmentation, sertraline, lithium, one night of sleep deprivation and two FDG PET scans
Other · Drug · Radiation
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2011
U.S. locations
2
States / cities
Irvine, California • La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 17, 2024 · Synced Oct 6, 2026, 10:38 AM EDT